Hybridan Small Cap Feast: 23/04/2024
* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced
Dish of the day
Admissions:
None
Delistings:
Bidstack Group (BIDS.L) has left the AIM market
What’s baking in the oven? **
Potential**** Initial Public Offerings:
None
Reverse Takeovers:
16 April 2024: Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radical Limited for a consideration of approximately £1.3m, payable by the issue of new ordinary shares in Electric Guitar. The Acquisition constitutes a reverse takeover under the Listing Rules and therefore shareholder approval for the Acquisition is being sought at a general meeting of Electric Guitar to be convened for 1 May 2024.
17 April 2024: TGI Fridays, Inc. (TGIF) announces that it has reached agreement on a non-binding basis for a proposed all-share acquisition of TGI Fridays, Inc. The Proposed Transaction would result in existing Hostmore shareholders holding 36% of the enlarged business upon completion (the Combined Group), with TGI Fridays shareholders holding a 64% shareholding. TGI Fridays is expected to be purchased for an enterprise value of £177m, or approximately 5.4x its FY23 underlying EBITDA. The Combined Group is expected to be renamed TGI Fridays plc, with its shares admitted to trading on the LSE’s Main Market. Completion of the Proposed Transaction expected to be by the end of Q3 2024.
Change of Market:
8 April 2024: a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated proposition as a value alternative to full price specialist retailers. The Company is listed on the premium segment of the Main market of the London Stock Exchange. The Company has announced its intention to change to the AIM market on 3 May 2024. Currently the market capitalisation of TheWorks is £16m.
Banquet Buffet***
0.16p £53.0m (88E.L)
The oil and gas exploration and production announces that it proposes to raise up to A$9.8m (approximately £5.23m), within the Company's existing placement capacity, pursuant to a placing of new ordinary shares at a price A$0.003 (equivalent to £0.0016) per share. The Placing Price is equivalent to a discount of 40% to the closing price on the Australian Securities Exchange on 22 April 2024. The net proceeds, together with the Company's existing cash reserves, will strengthen the Company's balance sheet and provide sufficient capital to fund Project Phoenix and Project Leonis in Alaska, as well as PEL 93 in Namibia.
132.5p £40.6m (AREC.L)
The biopharmaceutical group advancing today's therapies to enable healthier lives announces that Susan Lowther has decided to step down from her role as Chief Financial Officer, Company Secretary and as a Board Director, to pursue new opportunities. A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover.
0.068p £17.2m (BOIL.L)
The independent oil and gas exploration and production company provides a update regarding the changes to its Board of Directors and executive positions. John Wakefield has stepped down as Chairman of the Board with effect from 22 April 2024 and Gerry Aherne has now been appointed to the Board as Baron's new Independent Non-Executive Chairman with immediate effect. Jon Ford, Technical Director for Baron, has elected to step down from the Board at the end of April 2024. Jon will be retained by the Company as a part-time technical adviser. Dr John Chessher has joined the Board as an Independent Non-Executive Director with immediate effect. At the executive level, Rob Collins has been appointed as Baron's chief financial officer, currently a non-board position.
* 5p £5.1m (CCS.L)
The technology commercialisation company focused on cyber security and risk, announces its final results for the year ended 31 December 2023. Revenue increased 15% to £4.19m (2022: £3.65m), Loss before tax decreased to £4.14m (2022: £4.57m). Cash and cash equivalents decreased to £730k (2022: £2.08m). The Company is targeting strong revenue growth in 2024 and expects its revenue to be within 10% of our anticipated revenue of £7m, albeit at the lower end of the range. Crossword is on track to deliver EBITDA and cash breakeven on a monthly basis during the second half of 2024. A working capital fund raise is anticipated in 2024 to further support the drive to profitability.
98.5p £82.0m (ELCO.L)
The specialist software provider for the built environment announces its audited results for the year ended 31 December 2023. Total revenue increased 5% to £28.0m (2022: £26.6m). Profit before tax increased 13% to £3.4m (2022: £2.9m). Cash balance decreased to £10.9m (2022: £12.5m) due to M&A activity. As at 31 March 2024, Eleco’s ARR was £24.5m, indicating continued organic growth. Looking forward, the Group is trading in line with 2024 expectations.
8.5p £5.7m (GTC.L)
The locator of subsurface resources announces it has won a new contract with East Star Resources, a London-listed company focused on copper exploration, to locate porphyry copper deposits in Kazakhstan. The project is backed by the BHP Xplor 2024 accelerator programme and is the first time Getech's Globe geoscience platform will be used to locate porphyry copper. The contract win builds on the Company's joint venture agreement with East Star Resources, announced last month, to explore for sedimentary copper deposits in Kazakhstan. For this contract aimed at locating porphyry copper, the Company will receive a fee for exploration services.
40p £12.5m (ITIM.L)
The SaaS based technology company that enables store-based retailers to optimise their businesses to improve financial performance, announces that it has signed an additional professional services contract with toy retailer The Entertainer. The Entertainer Toy Shops will be opening in over 800 Tesco stores across the UK and Ireland, extending their partnership following a successful year long trial. The partnership will also see Tesco enter a supplier agreement with The Entertainer for the supermarket's stores across Central Europe. The execution of this contract is in line with the Company's financial expectations for the current financial year.
0.85p £2.3m (N4P.L)
The specialist pharmaceutical company developing Nuvec® a novel delivery system for cancer treatments and vaccines, announces its audited results for the year ended 31 December 2023. Loss before tax increased to £1.42m (2022: £1.19m). Cash and cash equivalents decreased t0 £1.03m (2022: £1.92m). Going forward, the Company is consolidating efforts on Nuvec® and actively seeking commercial solutions for the product.
* 30.5p £31.0m (SAR.L)
The clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer announces that it has issued 2,260,488 new Ordinary Shares to RiverFort Global Opportunities, in accordance with the terms of the Facility announced on 3 August 2023. The issuance of the Riverfort Shares will settle the full outstanding balance on the Riverfort Facility. As noted in Sareum's announcement of 28 March 2024, the Company does not intend to make any further withdrawals pursuant to the Riverfort Facility and accordingly the Company will not be issuing any further Subscription Shares pursuant to the Riverfort Facility.
42.725p £109.7m (WJG.L)
The developer and manager of residential-for-rent home announces that, as part of a managed succession process, Sarah Sergeant, Chief Financial Officer, will step down from the Board in mid-June 2024. Simon Jones has been appointed to succeed Sarah. Simon will join Watkin Jones as Chief Financial Officer Designate and as a member of the Board on 21 May 2024 and will work closely with Sarah to ensure a smooth hand over of responsibilities following the publication of the Group's interim results for the six months ended 31 March 2024.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.